Literature DB >> 22962266

Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin.

Jens O Schmid1, Meng Dong, Silke Haubeiss, Godehard Friedel, Sabine Bode, Andreas Grabner, German Ott, Thomas E Mürdter, Moshe Oren, Walter E Aulitzky, Heiko van der Kuip.   

Abstract

Current understanding of the p53 response is based mainly upon in vitro studies of homogeneous cell populations. However, there is little information on whether the same principles operate within heterogeneous tumor tissues that are comprised of cancer cells and other cell types, including cancer-associated fibroblasts (CAF). Using ex-vivo tissue cultures, we investigated p53 status and responses to cisplatin in tumor cells and CAFs from tissue specimens isolated from 32 lung cancer patients. By comparing cultivated tissue slices with the corresponding tumor tissues fixed immediately after surgery, we found that morphology, proliferation, and p53 staining pattern were preserved during cultivation. Unexpectedly, when CAFs were analyzed, p53 accumulation and induction of p21 was observed only in tumors with constitutively low p53 protein and accumulation upon cisplatin treatment. In contrast, in tumors with no p53 accumulation in cancer cells there was also no p53 accumulation or p21 induction in adjacent CAFs. Furthermore, induction of cisplatin-induced apoptosis in CAFs was selectively observed in tumors characterized by a parallel induction of cancer cell death. Our findings reveal an interdependence of the p53 response in cancer cells and adjacent CAFs within tumor tissues, arguing that cancer cells control the response of their microenvironment to DNA damage. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22962266     DOI: 10.1158/0008-5472.CAN-12-1201

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance.

Authors:  Pritish Nilendu; Sachin C Sarode; Devashree Jahagirdar; Ishita Tandon; Shankargouda Patil; Gargi S Sarode; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cell Oncol (Dordr)       Date:  2018-07-19       Impact factor: 6.730

2.  Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer.

Authors:  Toshihiro Ogawa; Satoru Kikuchi; Motoyasu Tabuchi; Ema Mitsui; Yuta Une; Hiroshi Tazawa; Shinji Kuroda; Kazuhiro Noma; Toshiaki Ohara; Shunsuke Kagawa; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Mol Ther Oncolytics       Date:  2022-04-25       Impact factor: 6.311

3.  Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features.

Authors:  Sharathchandra Arandkar; Noa Furth; Yair Elisha; Nishanth Belugali Nataraj; Heiko van der Kuip; Yosef Yarden; Walter Aulitzky; Igor Ulitsky; Benjamin Geiger; Moshe Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-04       Impact factor: 11.205

4.  ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma.

Authors:  Jun Li; Jie Ao; Kai Li; Jie Zhang; Yanyan Li; Le Zhang; Yuyan Wei; Di Gong; Junping Gao; Weiwei Tan; Lugang Huang; Lunxu Liu; Ping Lin; Yuquan Wei
Journal:  Cell Death Dis       Date:  2016-10-20       Impact factor: 8.469

5.  Genetic alterations and epigenetic alterations of cancer-associated fibroblasts.

Authors:  Heng Du; Guowei Che
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

Review 6.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

7.  Loss of p53 drives neuron reprogramming in head and neck cancer.

Authors:  Moran Amit; Hideaki Takahashi; Mihnea Paul Dragomir; Antje Lindemann; Frederico O Gleber-Netto; Curtis R Pickering; Simone Anfossi; Abdullah A Osman; Yu Cai; Rong Wang; Erik Knutsen; Masayoshi Shimizu; Cristina Ivan; Xiayu Rao; Jing Wang; Deborah A Silverman; Samantha Tam; Mei Zhao; Carlos Caulin; Assaf Zinger; Ennio Tasciotti; Patrick M Dougherty; Adel El-Naggar; George A Calin; Jeffrey N Myers
Journal:  Nature       Date:  2020-02-12       Impact factor: 69.504

8.  Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate.

Authors:  Sophia Lisette Maund; Rosalie Nolley; Donna Mae Peehl
Journal:  Lab Invest       Date:  2013-12-02       Impact factor: 5.662

9.  Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells.

Authors:  Katharina Leithner; Christoph Wohlkoenig; Elvira Stacher; Jörg Lindenmann; Nicole A Hofmann; Birgit Gallé; Christian Guelly; Franz Quehenberger; Philipp Stiegler; Freyja-Maria Smolle-Jüttner; Sjaak Philipsen; Helmut H Popper; Andelko Hrzenjak; Andrea Olschewski; Horst Olschewski
Journal:  BMC Cancer       Date:  2014-01-25       Impact factor: 4.430

10.  RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.

Authors:  A Weilbacher; M Gutekunst; M Oren; W E Aulitzky; H van der Kuip
Journal:  Cell Death Dis       Date:  2014-07-10       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.